Leadership Overview
PT. Inertia Utama has 4 executives leading key functions including technology, operations, and governance.
Driven by innovation, PT. Inertia Utama is dedicated to advancing the pharmaceutical industry through strategic leadership and operational excellence, impacting market dynamics with its specialized focus.
Driven by innovation, PT. Inertia Utama is dedicated to advancing the pharmaceutical industry through strategic leadership and operational excellence, impacting market dynamics with its specialized focus.
Leadership Roles at PT. Inertia Utama
Hery Sutanto - President & Director
Hery Sutanto, the President & Director at PT. Inertia Utama, spearheads the company's overall strategic direction and operational execution within the pharmaceutical industry. Sutanto's leadership guides the company's expansion efforts and ensures alignment with market demands in Indonesia. This executive role involves direct oversight of key business units, driving performance, and fostering a culture of excellence. By managing day-to-day operations, Hery Sutanto ensures that PT. Inertia Utama consistently delivers high-quality pharmaceutical products. The President & Director's responsibilities include cultivating strong relationships with stakeholders, partners, and regulatory bodies, thereby solidifying the company's market presence. Strategic decision-making regarding resource allocation and business development falls under Sutanto's purview, directly impacting the company's financial health and long-term sustainability. This executive's commitment to operational efficiency and market responsiveness is critical to PT. Inertia Utama's success.
Raymond Tjandrawinata - President & Commissioner
Raymond Tjandrawinata, the President & Commissioner at PT. Inertia Utama, provides high-level strategic oversight and governance for the pharmaceutical company. Tjandrawinata's role focuses on ensuring the company adheres to best practices in corporate governance and ethical operations within the Indonesian market. This executive position involves guiding the board's strategic decisions and ensuring long-term value creation for shareholders. By reviewing and approving major corporate policies, Raymond Tjandrawinata plays a crucial part in shaping the company's future trajectory. The President & Commissioner's responsibilities include monitoring financial performance, assessing market opportunities, and mitigating risks associated with the pharmaceutical sector. This leadership ensures that PT. Inertia Utama operates with integrity and maintains a strong reputation. Tjandrawinata's strategic vision is instrumental in navigating the complexities of the industry and driving sustainable growth for the organization.
Wimala Widjaja - Chief Information Officer
Wimala Widjaja, the Chief Information Officer at PT. Inertia Utama, directs the company's technology strategy and digital transformation initiatives. Overseeing all IT infrastructure, Widjaja ensures robust systems support the pharmaceutical operations in Tangerang Selatan. This leadership role involves managing data security, implementing advanced analytics for research and development, and optimizing operational workflows through technological integration. By driving innovation in information systems, Wimala Widjaja enhances efficiency and compliance within the highly regulated pharmaceutical sector. The Chief Information Officer's responsibilities extend to evaluating emerging technologies that can provide a competitive advantage, ensuring PT. Inertia Utama maintains its position in the Indonesian market. Strategic alignment with business objectives is paramount, as is fostering a culture of technological advancement across all departments. This executive's focus on secure and scalable IT solutions underpins the company's growth and operational integrity.
Ferry Soetikno - Direktur
Ferry Soetikno, the Direktur at PT. Inertia Utama, manages specific operational functions critical to the company's pharmaceutical manufacturing processes. Soetikno's direct involvement ensures the efficient production and quality control of pharmaceutical products, adhering to stringent industry standards in Tangerang Selatan. This leadership role involves overseeing production schedules, managing supply chain logistics, and implementing process improvements to enhance operational output. By focusing on manufacturing excellence, Ferry Soetikno contributes directly to PT. Inertia Utama's ability to meet market demand reliably. The Direktur's responsibilities include ensuring compliance with all relevant health and safety regulations, thereby safeguarding both employees and product integrity. This executive's dedication to operational efficiency and quality assurance is fundamental to the company's reputation and success in the competitive pharmaceutical landscape.
Explore Leadership Teams in Manufacturing
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CE
ST
PCI Pharma Services is an integrated full service provider to companies in the global healthcare industry. They offer services including analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage, and distribution. They are headquartered in Philadelphia, Pennsylvania with locations in the United States and Europe.
Company Leadership
BK
LR
HL
Founded in 1967, Douglas Pharmaceuticals is a manufacturer of pharmaceutical products. The company started out distributing prescription medicines, before manufacturing and later successfully researching and developing its products for export. The company is headquartered in Auckland, New Zealand.
Company Leadership SW
TB
CR
RD
Lotus Pharmaceutical is a global pharmaceutical company focused on developing, manufacturing, and commercializing generic and specialty medicines. It operates research and manufacturing facilities across Asia and supplies treatments for areas such as oncology, cardiovascular disease, and central nervous system conditions, aiming to improve access to affordable healthcare worldwide.
Company Leadership EC
VK
BS
Frequently Asked Questions Regarding PT. Inertia Utama Top Executives and Leadership Team
